- In February 2025, international medical societies published updated guidelines for the diagnosis and treatment of Candida infections. These guidelines recommend echinocandins, such as caspofungin, micafungin, anidulafungin, and the newer rezafungin, as first-line therapies for invasive candidiasis due to their broad activity and safety profiles. In addition, oteseconazole has been introduced as a treatment option for recurrent vulvovaginal candidiasis
- In April 2024, researchers at the University of Tokyo announced the development of a new combination therapy aimed at treating invasive Candida infections. This treatment combines micafungin, a well-known echinocandin, with a novel fungicidal agent that has shown promising results in preclinical trials, potentially providing a more effective solution for patients with antifungal-resistant infections
- In March 2023, the U.S. FDA approved rezafungin (brand name Rezzayo), a novel echinocandin antifungal, for the treatment of invasive candidiasis and candidemia. This once-weekly intravenous treatment offers a more convenient dosing schedule compared to daily alternatives, potentially improving patient adherence and outcomes
- In April 2022, the U.S. FDA approved oteseconazole (brand name VIVJOA), a selective CYP51 inhibitor, for the treatment of recurrent vulvovaginal candidiasis (RVVC) in women who are not of reproductive potential. This approval marked oteseconazole as the first FDA-approved medication specifically for RVVC. Clinical studies demonstrated that oteseconazole significantly reduced the incidence of RVVC recurrence over a 50-week period
- In December 2021, Cidara Therapeutics, Inc. and Mundipharma announced positive topline results from the pivotal ReSTORE Phase 3 clinical trial, which evaluated the efficacy and safety of rezafungin, a once-weekly antifungal treatment, as a first-line option for candidemia and invasive candidiasis
